Curia (RNA/Advanced) vs Nitto Denko Avecia: CDMO Comparison
How does Curia (RNA/Advanced) compare to Nitto Denko Avecia?
As of Mar 2026, Curia (RNA/Advanced): 2 FDA inspections (including 1 NAI, 1 VAI and 0 OAI), 18 EMA/MHRA GMP certificates. Signal Score 79.5. Nitto Denko Avecia: 4 FDA inspections (including 3 NAI, 1 VAI and 0 OAI). Signal Score 80.3. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Curia (RNA/Advanced) and Nitto Denko Avecia on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Curia (RNA/Advanced) holds 18 active EMA GMP certificates; Nitto Denko Avecia does not appear in EudraGMDP.
Across the cross-modality scorecard, Nitto Denko Avecia carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Curia (RNA/Advanced) vs Nitto Denko Avecia
How does Curia (RNA/Advanced) compare to Nitto Denko Avecia?
On CDMO Signal's composite Signal Score, Curia (RNA/Advanced) is 80/100 and Nitto Denko Avecia is 80/100; Curia (RNA/Advanced) has 2 FDA inspections on record vs 4 for Nitto Denko Avecia; European coverage is 18 active EMA+MHRA certificates for Curia (RNA/Advanced) vs 0 for Nitto Denko Avecia. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Curia (RNA/Advanced) or Nitto Denko Avecia?
Both Curia (RNA/Advanced) and Nitto Denko Avecia maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Curia (RNA/Advanced) has 2 FDA inspections on record; Nitto Denko Avecia has 4.
How do Curia (RNA/Advanced) and Nitto Denko Avecia compare on European GMP coverage?
Curia (RNA/Advanced) holds 18 active EMA GMP certificates and 0 MHRA / UK certificates. Nitto Denko Avecia holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
Curia (RNA/Advanced) carries a Signal Score of 80/100 and Nitto Denko Avecia carries 80/100 — essentially tied for Nitto Denko Avecia. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →